Vitamin A ( DrugBank: Vitamin A )
3 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 5 |
| 53 | シェーグレン症候群 | 1 |
| 90 | 網膜色素変性症 | 5 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01407211 (ClinicalTrials.gov) | April 2011 | 14/2/2011 | Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient | The Impact of Vitamin A Supplementation on Gene Expression of Cytokine Secreted by CD4+ T Lymphocyte in Multiple Sclerosis Patients | Relapsing Remitting Multiple Sclerosis | Dietary Supplement: vitamin A | Tehran University of Medical Sciences | NULL | Enrolling by invitation | 20 Years | 45 Years | Both | 30 | Phase 4 | Iran, Islamic Republic of |
| 2 | EUCTR2010-023677-19-IT (EUCTR) | 23/03/2011 | 10/06/2011 | Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010 | Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010 | PATIENT WITH RRMS AND SPMS MedDRA version: 13.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;System Organ Class: 10029205 - Nervous system disorders | Trade Name: BETAFERON*15CONFEZ 0,25MG/ML+ INN or Proposed INN: Interferon beta-1b Trade Name: EXTAVIA*SC 15FL 250MCG/ML+15SI INN or Proposed INN: Interferon beta-1b Trade Name: DIBASE INN or Proposed INN: Colecalciferol | AZIENDA OSPEDALIERA S. LUIGI GONZAGA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 3 | NCT01705457 (ClinicalTrials.gov) | February 2010 | 9/10/2012 | Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis | Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients | Relapsing Remitting Multiple Sclerosis | Drug: Dietary Supplement: vitamin A;Drug: placebo | Tehran University of Medical Sciences | NULL | Enrolling by invitation | 20 Years | 45 Years | Both | 20 | Phase 4 | Iran, Islamic Republic of |
| 4 | NCT01417273 (ClinicalTrials.gov) | February 2010 | 17/11/2010 | Impact of Vitamin A on Multiple Sclerosis (MS) | Impact of Vitamin A Supplementation on Disease Activity and Progression in Multiple Sclerotic (MS) Patients | Relapsing Remitting Multiple Sclerosis | Dietary Supplement: vitamin A;Drug: Drug: placebo | Tehran University of Medical Sciences | NULL | Enrolling by invitation | 20 Years | 45 Years | Both | 100 | Phase 4 | Iran, Islamic Republic of |
| 5 | NCT01225289 (ClinicalTrials.gov) | October 2009 | 6/9/2010 | Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients | The Study of the Effects of Vitamin A Supplementation on Immune System and Th1/Th2 Balance in Patients With Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Dietary Supplement: Vitamin A;Drug: Placebo | Tehran University of Medical Sciences | NULL | Completed | 20 Years | 45 Years | All | 36 | Phase 4 | Iran, Islamic Republic of |
53. シェーグレン症候群
臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000013234 | 2014/04/01 | 01/04/2014 | Effect of the dual treatment of diquafosol sodium and rebamipide on dry eye syndrome related to chronic graft versus host disease and Sjogrens syndrome | Effect of the dual treatment of diquafosol sodium and rebamipide on dry eye syndrome related to chronic graft versus host disease and Sjogrens syndrome - Effect of diquafosol sodium and rebamipide on GVHD and Sjogrens syndrome related dry eye. | Dry eye related to chronic GVHD and Sjogren s syndrome | Diquafosol sodium and rebamipide ophthalmic solution Artifical tears, vitamin A ophthalmic solution, or/and sodium hyaluronate ophthalmic solution | Keio University School of Medicine | NULL | Complete: follow-up complete | 20years-old | 75years-old | Male and Female | 20 | Not applicable | Japan |
90. 網膜色素変性症
臨床試験数 : 147 / 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02465749 (ClinicalTrials.gov) | May 2015 | 22/5/2015 | Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa | Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Continuous oxygen;Device: blue light-absorbing sunglasses;Drug: Compound thrombosis capsule sig: 1.5g/tid;Drug: Ginkgo biloba pills sig: 300mg/tid;Drug: Vitamin B sig: 10mg/tid;Drug: Vitamin AD sig: 1 tablet/tid | Sun Yat-sen University | Zhujiang Hospital;Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;Guangzhou Jeeyor Medical Research Co.,Ltd. | Not yet recruiting | 18 Years | 60 Years | Both | 404 | Phase 0 | China |
| 2 | NCT00065455 (ClinicalTrials.gov) | July 17, 2003 | 23/7/2003 | Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa | Pilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Vitamin A | National Eye Institute (NEI) | NULL | Completed | 18 Years | N/A | All | 11 | Phase 1 | United States |
| 3 | NCT00346333 (ClinicalTrials.gov) | July 2003 | 27/6/2006 | Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A | Randomized Clinical Trial for Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Lutein;Dietary Supplement: Cornstarch control | National Eye Institute (NEI) | NULL | Completed | 18 Years | 60 Years | All | 240 | Phase 3 | United States |
| 4 | NCT00000116 (ClinicalTrials.gov) | May 1996 | 23/9/1999 | Randomized Trial for Retinitis Pigmentosa | Randomized Trial for Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Vitamin A;Drug: Nutritional Supplement | National Eye Institute (NEI) | NULL | Completed | 18 Years | 56 Years | Both | Phase 3 | United States | |
| 5 | NCT00000114 (ClinicalTrials.gov) | May 1984 | 23/9/1999 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Vitamin E;Drug: Vitamin A | National Eye Institute (NEI) | NULL | Completed | 18 Years | 49 Years | Both | Phase 3 | NULL |